McMaster University | HEALTH FORUM

Living Evidence Profile

Identifying features and impacts of public health strategies that can be used to prevent, reduce, and/or mitigate avian influenza spillover to humans

17 May 2024

[MHF product code: LEP 8.2] *Note that this product was previously labelled as rapid evidence profile #64 but has since been changed to a living evidence profile.

+ Global evidence drawn upon

Evidence syntheses selected based on relevance, quality, and recency of search

- Forms of domestic evidence used (🍁 = Canadian)

Evaluation

- Other types of information used

Jurisdictional scan

10 countries (AU, BR, CB, CH, FR, JP, NZ, SG, UK, US), in addition to international organizations and Canadian provinces and territories

*** Additional notable features**

Prepared in three business days using an 'all hands on deck' approach

Context

- Avian influenza is commonly found in birds, but it can also infect non-human mammals (e.g., cats, foxes, bears) and humans.
- Human infections typically occur after exposure through close contact with infected birds or in highly contaminated environments like poultry farms and live animal markets.
- The risk of human infection with avian influenza A is low for the general public but may be higher for certain populations.
- Recently, a multi-state outbreak of highly pathogenic avian influenza A(H5N1) in dairy cows was reported on 25 March 2024 in the United States, which has been noted as being reflective of the continued spread of clade 2.3.4.4b viruses that entered the U.S. in late 2021.(1; 2)
- At time of writing this living evidence profile on 17 May 2024, the U.S. Centers for Disease Control and Prevention (CDC) had confirmed one human A(H5N1) infection and, while there is uncertainty about whether the infection was due to exposure to dairy cattle in Texas with presumed infection or a contaminated environment, this is likely the first instance of mammal-to-human transmission.(2)
- As an emerging infectious disease with pandemic potential and the new outbreak in dairy cattle, it is important to identify effective upstream and downstream public health strategies (particularly those using a One Health approach) to prevent, reduce, and/or mitigate the risk of avian influenza spillover into humans.
- This living evidence profile (LEP) was originally requested to inform initial deliberations about such public health strategies and was therefore focused on identifying existing evidence syntheses where single studies were identified and synthesized.
- This update to the LEP includes: 1) an update on the original literature search for evidence syntheses; 2) a search for any single studies that we could identify about transmission involving cattle or other livestock, as well as transmission risk to livestock workers, given the recent outbreak in the U.S; and 3) a jurisdictional scan to provide more detailed insights from other countries and Canadian provinces and territories on public health strategies related to avian influenza.

Question

- What are the features and impacts of public health strategies, particularly those that adopt a One Health approach, that can contribute to preventing, reducing, and/or mitigating the risk of avian influenza spillover into humans?

High-level summary of key findings

- In addition to the 11 evidence syntheses identified in the original evidence profile, in this update we identified one new rapid review and four pre-print studies related to public health strategies to prevent, reduce, and/or mitigate avian influenza spillover to humans.
- The rapid review found that using convalescent plasma as a passive immunotherapy treatment against avian influenza prior to infection was more efficacious than treatment after infection, and the pre-print studies explored the effectiveness of wastewater monitoring of avian influenza and existing healthcare surveillance strategies in the U.S.
- Only two of the 11 evidence syntheses identified in the original evidence profile briefly mentioned One Health.
- Infection prevention training for healthcare workers was identified as significantly reducing risk of infection from respiratory viruses among healthcare workers involved in endotracheal intubations.
- Enhanced sharing of production and trade data within commercial poultry networks was also identified as an informational strategy important for supporting mitigation strategies for the global spread of avian influenza.
- Several non-pharmaceutical measures were found to be effective at preventing infection with avian influenza, including using personal protective equipment, physical distancing

Box 1: Approach and supporting materials

We identified evidence addressing the question by searching ACCESSSS, Health Systems Evidence, Health Evidence, and PubMed for full evidence syntheses (or synthesis-derived products such as overviews of evidence syntheses) and protocols for evidence syntheses. These searches were last conducted on 13 May 2024 and were not limited by publication date except in PubMed, which was limited to literature published from the last five years (2019 onwards). We also conducted a search for single studies in PubMed and the United States Department of Agriculture (USDA) National Agricultural Library relevant to dairy cattle, other non-human mammals (including ruminants), transmission associated with dairy products, and risk to livestock. In addition, we conducted searches for pre-prints in medRxiv and bioRxiv from 1 January 2024 to 13 May 2024. The search strategies used are included in Appendix 1.

We hand searched government and stakeholder websites of other select countries (Australia, Brazil, Cambodia, China, France, Japan, New Zealand, Singapore, United Kingdom, and United States), international organizations (World Health Organization, Pan American Health Organization, World Organisation for Animal Health, European Centre for Disease Prevention and Control, and Food and Agriculture Organization), and Canadian provinces and territories to identify any publicly available information published since 1 February 2024. A full list of sources is included in Appendix 8.

In contrast to synthesis methods that provide an in-depth understanding of the evidence, this profile focuses on providing an overview and key insights from relevant documents. Note that the timing, frequency, and scope of future updates of this LEP will be determined in collaboration with the requestor.

A separate appendix document includes:

1) Methodological details (Appendix 1)
2) Key findings from evidence documents (Appendix 2)
3) Key findings jurisdictional scans (Appendix 3)
4) Details about each identified evidence synthesis (Appendix 4)
5) Details about each identified single study (Appendix 5)
6) Details about experiences identified in international organizations and other countries (Appendix 6)
7) Details about experiences in Canadian provinces and territories (Appendix 7)
8) Key list of sources used for jurisdictional scans (Appendix 8)
9) Documents that were excluded in the final stages of review (Appendix 9)

This living evidence profile was prepared in the equivalent of a half day 'full court press' by all involved staff.

in schools, and live poultry market interventions (e.g., quarantine access systems, physically separating poultry from different sources, disinfection and decontamination, daily cleaning, rest days, live poultry market closures).

- Vaccinations in humans was identified as the primary pharmaceutical measure used as part of public health strategies, with a favourable safety profile and immunogenicity of A(H5N1) and A(H7N9) vaccines.
- A(H5N1) and A(H5N2) vaccines appear to be efficacious in protecting chickens from morbidity and mortality.
- Additional research is needed to address several gaps in the literature, including strategies related to non-pharmaceutical measures to control the spread of infections, surveillance, and reporting.
- We conducted a jurisdictional scan of select countries (Australia, Brazil, Cambodia, China, France, Japan, New Zealand, Singapore, United Kingdom, and United States), international organizations (World Health Organization (WHO), Pan American Health Organization (PAHO), World Organisation for Animal Health (WOAH), European Centre for Disease Prevention and Control (ECDC), and Food and Agriculture Organization (FAO)), and Canadian provinces and territories to identify any relevant publicly available information published since 1 February 2024 about public health strategies that can be used to prevent, reduce, and/or mitigate avian influenza spillover to humans.
- In addition to monitoring the prevalence of avian influenza cases globally through routine risk assessments, WOAH and WHO provide recommendations for those in contact with sick or suspected animals.
- The Federal Drug Agency (FDA) in the U.S. has continued a stepwise approach to scientific analysis of commercial milk safety in order to test the efficacy of the pasteurized milk ordinance on the elimination of known pathogens in the milk supply.
- Border control measures were implemented by Singapore, Japan, and Canada in response to cases of avian influenza in birds and livestock in recent months, and a vaccination plan for farmed ducks has been implemented by France as a preventive measure.
- The Canadian Food Inspection Agency (CFIA) in collaboration with Health Canada and the Public Health Agency of Canada (PHAC) has been proactively testing commercial milk samples across Canada to detect fragments of the virus, and as of 14 May 2024, all tested samples have been negative for fragments of highly pathogenic avian influenza (HPAI).
- Most international and Canadian jurisdictions provide information to the public about the aetiology, diagnosis, treatment, prevention, control, and surveillance and management of avian influenza on their public health websites.

Framework to organize what we looked for

- Public health strategies
  - Information and education provision
  - Non-pharmaceutical measures to prevent infection
    - Avoiding sources of exposure (e.g., reducing contact with infectious birds, animals, or environments)
    - Using personal protective equipment (e.g., masks, gloves)
    - Washing hands
    - Physical distancing
    - Following safe food handling procedures and recommended cooking temperatures
    - Farm and market biosecurity measures (e.g., ventilation, controlled access, cleaning and disinfection practices)
  - Non-pharmaceutical measures to control the spread of infections
    - Case and contact management
    - Isolation and quarantine
    - Border control measures
  - Pharmaceutical measures used as part of public health strategies
    - Vaccinations (in animals)
    - Vaccinations (in humans)

        - Antiviral medications
    - Surveillance and reporting
- Priority populations
    - Groups at higher risk of exposure
        - Working on a commercial poultry farm (e.g., producers), including seasonal/migrant workers
        - Working with non-commercial or backyard flocks
        - Livestock farm worker/small herd owner
        - Breeding and handling birds (e.g., dealer, breeder of exotics, falconry, racing pigeons)
        - Hunting and trapping wild birds and mammals (e.g., Indigenous harvesters)
        - Working with live or recently killed poultry, cattle, or other livestock (e.g., butcher, processing plant worker, poultry culler)
        - Working with unpasteurized milk products (e.g., milk processing plant worker, cheesemaker)
        - Veterinarians, veterinary staff
        - Working with wild birds and/or mammals for healthcare, research, and conservation (e.g., laboratory workers, researchers, biologists, wildlife rehabilitators, persons permitted to perform bird branding, capturing, sampling, removal, restoration)
        - Working with non-human mammals that commonly eat wild birds
        - Working or visiting live bird or mammal markets
        - Working with or caretaking of animals that regularly interact with wild birds (e.g., caretakers, pets, guardian dogs, hunting dogs, mink/fur animal farmer)
        - Working in healthcare settings and other contacts of cases (if human-to-human transmission starts)
    - Other equity considerations
- Outcomes
    - Reduction in risk of exposure
    - Zoonotic infections
    - Human-to-human infections
    - Health-related outcomes for individuals infected

What we found

Key findings from evidence documents

In addition to the 11 evidence syntheses identified in the original evidence profile, in this update we identified one new rapid review and four pre-print studies related to public health strategies to prevent, reduce, and/or mitigate avian influenza spillover to humans. Most of the new evidence focused on strategies for surveillance and monitoring of avian influenza outbreaks. No relevant peer-reviewed single studies were identified. Due to the limited number of highly relevant evidence documents included, we incorporated findings from medium and low relevance documents in the summary below.

Information and education provision

In terms of information and education-related public health strategies, a medium-quality evidence synthesis (low relevance) that focused on front-line healthcare workers found that infection training for those who are involved in endotracheal intubations can significantly reduce their risk of infection from respiratory viruses.(3) Using a systems-level approach, another medium-quality evidence synthesis (medium relevance) highlighted the need for sharing of production and trade data between private and public sectors within commercial poultry networks to facilitate data access and inform policies that can support mitigation strategies for the global spread of avian influenza.(4) We did not identify any new evidence on information and education-related public health strategies.

Non-pharmaceutical measures to prevent infection

Several non-pharmaceutical measures to prevent infection with avian influenza were identified, including using personal protective equipment, physical distancing, and farm and market biosecurity measures. Personal protective measures (e.g., gloves, gowns, surgical masks, N95 respirators) for front-line healthcare workers were found to be effective, and school closures were identified as a strategy to prevent the spread of A(H5N1) in Australia (from low relevance evidence syntheses).(3; 5; 6) One medium-quality evidence synthesis identified live poultry market interventions including quarantine access systems, physically separating poultry from different sources, disinfection and decontamination, daily cleaning, rest days, and live poultry market closures. These interventions supported a decrease in incidence of avian influenza viruses at live poultry market settings.(7) We did not identify any new evidence on non-pharmaceutical measures to prevent infection.

Pharmaceutical measures used as part of public health strategies

Vaccination in humans was identified as a pharmaceutical measure used as part of public health strategies. An Andalusian Agency for Health Technology Assessment reported in a medium-quality evidence synthesis that an inactivated split-virion formulation of the pre-pandemic A(H5N1) influenza vaccine, which includes a low antigen dose and an oil-in-water emulsion-based adjuvant, had a favourable safety profile and immunogenicity.(8) This finding was supported by another medium-quality evidence synthesis that reported that two doses of 7.5 µg of oil-in-water emulsion-adjuvanted A(H5N1) vaccine induced a robust antibody response and was well-tolerated among older adults.(9) We identified a low-quality evidence synthesis that found reduced responses to A(H5N1) influenza vaccination in individuals who had received the seasonal influenza vaccine.(10) Additional research is needed to better understand the reduced immune responses. A newly identified pre-print study highlighted that the delivery of multivalent influenza vaccines from self-assembled, injectable polymer-nanoparticle (PNP) hydrogels induced consistent, rapid, and potent humoral immune responses against both heterologous and homologous virus subtypes, including A(H5N1).(11) This finding demonstrates that the use of PNP hydrogels with influenza vaccines can be an effective strategy for generating lasting immunity to influenza. Lastly, we identified one medium-quality evidence synthesis that concluded that adjuvanted A(H7N9) vaccines for humans were immunogenic and safe in healthy individuals.(12)

Vaccinations in chickens were identified in two medium-quality evidence syntheses. One evidence synthesis described that both inactivated and recombinant fowlpox virus expressing A(H5) vaccines (for A(H5N1) and A(H5N2)) were efficacious in protecting chickens from morbidity and mortality.(13) The other evidence synthesis indicated that recombinant herpesvirus of turkeys (rHVT) and inactivated replicating viral-vectored vaccines offered advantages to induce broader immunity as they were more tolerant of the variation in the hemagglutinin 1 domain.(14)

The newly identified rapid review explored evidence on the use of convalescent plasma (CP) as a passive immunotherapy treatment against avian influenza (A(H5N1)) in humans and found that CP treatment given prior to infection was more efficacious than treatment after infection.(15) However, given concerns about infectivity of potential CP donors and the lack of historical studies on A(H5N1) virus isolation from CP, it is likely that efforts to use CP in treatment will be limited by a lack of pathogen reduction technologies.

Surveillance and reporting

Three of the pre-print studies identified in the updated search for this version of the LEP were focused on surveillance and reporting public health strategies. Two of the studies explored the use of wastewater monitoring following the recent emergence of avian influenza (A(H5N1)) in dairy cattle in the United States. In one study, researchers used an agnostic, hybrid-capture sequencing approach and detected avian influenza subtype A(H5N1) in wastewater in nine Texas cities between 4 March and 25 April 2024, with the best sequencing reads aligning to clade 2.3.4.4b.(16) In the other study, researchers developed an RT-PCR assay for the A(H5) marker and used it as part of

a wastewater monitoring strategy to detect the A(H5) gene in samples from three wastewater plants in the U.S. that were tested in the spring of 2024.(17) At two of the U.S. plants tested, researchers discovered that discharges from animal waste and milk by-products were permitted to discharge into the sewer system, highlighting the need to consider agricultural and industrial inputs into waste. Finally, researchers of the third study used a probabilistic framework to determine that novel influenza virus cases in the United States are likely to be detected using the existing healthcare surveillance strategies in the U.S. for community and healthcare settings, with the efficiency of the testing setting being directly impacted by the severity of disease in the setting.(18)

Gaps in existing evidence documents

There continues to be gaps in the literature about public health strategies related to non-pharmaceutical measures to control the spread of infections and a limited number of highly relevant evidence documents. While future studies on surveillance efforts are likely to be published, additional evidence is still needed to explore and understand public health strategies that can help to prevent the spread of avian influenza in animals and transmission to humans.

Key findings from our jurisdictional scan

We conducted a jurisdictional scan of select countries (Australia, Brazil, Cambodia, China, France, Japan, New Zealand, Singapore, United Kingdom, and United States), international organizations (WHO, PAHO, WOAH, ECDC, and FAO), and Canadian provinces and territories to identify any relevant publicly available information published since 1 February 2024 about public health strategies that can be used to prevent, reduce, and/or mitigate avian influenza spillover to humans.

International jurisdictions

Information and education provision

In terms of information and education, most international jurisdictions provide information to the public about the aetiology, diagnosis, treatment, prevention, control, and surveillance and management of avian influenza on their public health websites. Some jurisdictions, such as Australia, have used fact sheets to update the public on safety precautions for avian influenza, while Health New Zealand Te Whatu Ora offers a control manual for managing highly pathogenic avian influenza for public health professionals. In Cambodia, the government uses their national Facebook page and telegram channel to communicate with the public about avian influenza outbreaks.

Non-pharmaceutical measures to prevent infection

WOAH and the WHO provides recommendations for those in contact with sick or suspected infected animals, including hand hygiene, using personal protective equipment, avoiding the use and consumption of raw milk products, and implementing strict biosecurity measures in livestock holdings. These measures are echoed by ministries of health in international jurisdictions, including Cambodia, Singapore, Health Commission of Guangdong Province in China, the U.K., and the U.S. Specific recommendations have been made for farmers, poultry and backyard bird flock owners in the U.S. by the CDC, including that farmers should receive training in wearing, putting on and taking off personal protective equipment.

Non-pharmaceutical measures to control spread

In terms of case and contact management internationally, all member states under the International Health Regulations (2005) are required to notify the WHO immediately of any laboratory-confirmed case of a recent human avian influenza infection. Animal cases should also be reported to WOAH through the World Animal Health Information System and genetic sequences should be shared in publicly available databases. As a precaution, in early 2024 the Ministry of Agriculture, Forestry and Fisheries of Japan announced that 50,000 birds were culled in

Central Japan, and 14,000 birds in the southern Japanese prefecture of Kagoshima were culled after the confirmation of avian influenza outbreaks in both locations. Border-control measures were implemented in Singapore on 29 April 2024 by the National Parks Board/Animal & Veterinary Service (NParks/AVS) with a temporary ban on the importation of poultry and poultry products from Gifu prefecture after an outbreak of HPAI in poultry in Chiba prefecture, Japan. The Animal & Veterinary Service (AVS) also requires countries exporting poultry, poultry products and eggs to Singapore to be free from highly pathogenic avian influenza A(HPAI) and H5/H7 low pathogenicity avian influenza (LPAI). While the WHO did not advise any traveller screening for avian influenza at the time of writing of this report, WOAH recommends that any import risk management should be scientifically justified.

Pharmaceutical measures used as part of public health strategies

Vaccinations in animals against avian influenza was the primary pharmaceutical measure identified in international jurisdictions. The WHO Global Influenza Surveillance and Response System (GISRS) in collaboration with FAO and WOAH maintain a database of candidate vaccines (including regular genetic and antigenic characterization of contemporary zoonotic influenza viruses). WOAH recommends that individuals should consider poultry vaccination to prevent the spread of avian influenza. France took the proactive step of developing a vaccination plan for livestock that is financed by the state and professionals. As of 6 May 2024, a total of 32,453,950 ducks have been vaccinated against the avian influenza in France. In addition to this, as of 16 January 2024, no new outbreaks in poultry have been detected in France, with only 10 outbreaks confirmed in farmed birds for the 2023–2024 season. In New Zealand, a controlled trial of the Poulvac Flufend RG vaccine for five endangered native bird species has been approved. Finally, while the U.K. is not vaccinating poultry or captive birds against avian influenza, some zoo birds in England can get authorization for vaccination.

In terms of vaccinations in humans, the Ministry of Health of Singapore reported treatment for human infection with the bird flu virus varies based on symptoms and that recent A(H5N1) viruses are susceptible to oseltamivir. However, there are reports of resistance to the M2 inhibitors (amantadine and rimantadine). In the U.S., the CDC recommends that symptoms of persons with bird or other animal exposures should be treated with antiviral treatment (oseltamivir) while awaiting laboratory results or with chemoprophylaxis, which can be considered for any individual meeting epidemiologic exposure criteria.

Surveillance and monitoring

Internationally, situation reports on the state of avian influenza spread around the world are issued regularly by WOAH, with the most recent update from 3 May 2024. The WHO also provides regular risk assessments of influenza at the human-animal interface, and PAHO released an epidemiological update of A(H5N1) on 20 March 2024 and provided guidance to member states. In Brazil, the Ministry of Agriculture and Livestock, which monitors and records avian influenza outbreaks in the country, declared an animal health emergency for 180 days on 22 May 2023, and subsequently extended it for another 180 days after 139 outbreaks were identified. The U.K. has developed a mitigation strategy for avian influenza in wild birds in England and in Wales (last updated 18 March 2024) whereby virologists and epidemiologists collaborate with colleagues to share data on outbreaks in poultry, captive birds, and those found in wild birds. In the U.K., the Animal and Plant Health Agency carries out year-round surveillance for avian influenza in dead wild birds and mammals through the routine testing of animals found dead. Finally, in the U.S., as of 10 May 2024, the FDA in the U.S. has continued a step-wise approach to scientific analysis of commercial milk safety, which included taking 297 retail dairy samples (all of which have been negative for the live A(H5N1) virus) and continues to test the efficacy of the pasteurized milk ordinance on the effective elimination of known pathogens in the milk supply. The U.S. CDC and USDA are undertaking widespread monitoring, which includes case reporting, public health laboratory monitoring, clinical laboratory trends, emergency department trends, and wastewater surveillance.

Canadian jurisdictions

Information and education provision

Within Canada, PHAC provides guidelines on handling wildlife to protect health for hunters, people who work with wildlife, and members of the public, as well as guidance on human health issues and information for health professionals and the public about avian influenza A(H5N1) transmission, symptoms, and treatment on their website. CFIA provides national biosecurity standards, protocols and strategies for those in the poultry and dairy service industry as well as information to the public on their website on facts about avian influenza. Most provinces provide information on the signs, transmission, and prevention measures of avian influenza in poultry on their provincial health ministry's website. The Canadian Wildlife Health Cooperative also has a Dashboard where it displays suspected and confirmed cases of A(H5Nx) infections in wildlife.

Non-pharmaceutical measures to prevent infection

In terms of non-pharmaceutical measures taken within Canadian provinces and territories, PHAC outlines specific recommendations for infection prevention for individuals involved in avian influenza outbreak situations, including avoiding touching of the face and mucous membranes, cleaning hands frequently, and wearing personal protective equipment. Most provincial and territorial governments provide non-pharmaceutical recommendations for those exposed to or handling birds or other wildlife and those living in or having travelled to an area with A(H5N1), including British Columbia, Alberta, Manitoba, Saskatchewan, Ontario, Quebec, New Brunswick, Yukon, and Nunavut. Some of the recommendations include having proper hand hygiene, using personal protective equipment, avoiding the use and consumption of raw milk products, avoiding surfaces with bird dropping, properly cooking dishes with poultry and eggs, and implementing strict biosecurity measures in livestock holdings. Biosecurity recommendations for commercial poultry flocks from the Ontario government include measures that ensure both exclusion and containment access management, health management, and operational management of flocks.

Non-pharmaceutical measures to control spread

For animal health response within Canada, cattle producers, consumers and veterinarians in Canada are advised to report any suspected detection of HPAI infection in animals to CFIA. The CFIA continues to support provinces, territories, and industry in managing disease outbreaks in animals. For example, in response to an A(H5N1) outbreak detected 19 February 2024 at a commercial poultry operation in Mountain View County, Alberta, CFIA declared a primary control zone around the poultry farm, preventing the movement of birds, their products, and by-products as well as things exposed to the birds into, out of, within, or through the zone without permission from the agency. To manage human contacts after exposure to avian influenza in the community, PHAC recommends that public health authorities actively monitor contacts, evaluate contacts for antiviral prophylaxis and/or immunization, and implement measures to reduce the risk of spread. In terms of border measures, as of 29 April 2024, CFIA requires an addendum to the export certificate of cattle imported from the U.S. that certifies that the lactating dairy cows have tested negative by PCR for influenza A virus at a Canadian Animal Health Laboratory Network laboratory, have not been in a location where HPAI has been detected during the 60 days prior to exportation, and if they tested positive for influenza A virus, have completed a 60-day waiting period and have re-tested negative.

Pharmaceutical measures used as part of public health strategies

In terms of public health strategies that use pharmaceutical measures, PHAC's guidance document on human health issues related to avian influenza described high-level recommendations for the use of antivirals for the treatment of avian influenza, including oseltamivir for treatment and post-exposure prophylaxis in individuals over one year of age after close contact with an infected individual. According to PHAC, while there are no widely available influenza

A(H5N1) vaccines for public use in Canada, the decision to use a targeted vaccine for H5 influenza on individuals in Canada would depend on the risk of infection during an outbreak.

Surveillance and reporting

CFIA in collaboration with Health Canada and PHAC has been proactively testing commercial milk samples across Canada to detect fragments of the virus. As of 14 May 2024, all tested samples have been negative for fragments of HPAI A(H5N1).

The Canadian Wildlife Health Cooperative (CWHC), CFIA, and ECCC maintain a dashboard that displays suspected and confirmed cases of HPAI in wildlife in Canada. The dashboard provides data on suspected and confirmed cases, which can be filtered by province and species. Between January 2022 and March 2024, over 3,000 suspected and confirmed positive cases were reported in Canada across both birds and mammals. According to a 15 May 2024 update from the federal government of Canada, throughout the current outbreak of A(H5N1) in poultry in Canada, over 11 million domestic birds have been estimated to have been affected by HPAI. Estimates of the number of birds in infected flocks are provided for each province. In addition, Manitoba's Small Flock Avian Influence Program and the Saskatchewan Small Flock Poultry Surveillance Program allow small flock owners to submit dead birds for testing in the presence of potential signs of avian influenza. The Yukon government's site encourages civilian reporting of potential cases in live birds through the TIPP system (Turn in Poachers and Polluters) and provides contact information of the Yukon's Animal Health Unit.

Next steps

Several gaps exist in the existing evidence syntheses and jurisdictional scans about public health strategies to prevent, reduce, and/or mitigate avian influenza spillover to humans that could be the focus of future evidence syntheses and jurisdictional scans. These include:

- One Health approaches that focus on human, animal, and environmental health (we only identified two evidence syntheses that briefly mentioned One Health in passing) (4;5)
- non-pharmaceutical measures used globally to control the spread of avian influenza infections in humans and animals
- public health strategies focused on surveillance and reporting of avian influenza infections in humans and animals
- public health measures that are specifically tailored to priority populations that are at higher risk of exposure to avian influenza (e.g., commercial farm workers)
- variations in immune response in humans and animals because of influenza vaccinations
- additional pharmaceutical and non-pharmaceutical measures being taken within provinces and territories in Canada to control the spread of avian influenza.

References

1. Burrough ER MD, Petersen B, Timmermans SJ, Gauger PC, Zhang J, Siepker C, Mainenti M, Li G, Thompson AC, Gorden PJ, Plummer PJ, Main R. Highly Pathogenic avian influenza A (H5N1) clade 2.3. 4.4 b virus infection in domestic dairy cattle and cats, United States, 2024. *Emerging Infectious Diseases* 2024; 30(7):1335-134.
2. U.S. Centers for Disease Control and Prevention. Current H5N1 bird flu situation in dairy cows [press release]. Atlanta, GA: CDC; May 2024. Available from: https://www.cdc.gov/bird-flu/situation-summary/mammals.html (accessed 30 July 2024).
3. Chin KJ, Englesakis M, Lee Y, et al. Risk factors and protective measures for healthcare worker infection during highly infectious viral respiratory epidemics: A systematic review and meta-analysis. *Infection Control & Hospital Epidemiology* 2022; 43(5): 639-650.
4. Hautefeuille C, Dauphin G, Peyre M. Knowledge and remaining gaps on the role of animal and human movements in the poultry production and trade networks in the global spread of avian influenza viruses - A scoping review. *PLoS One* 2020; 15(3): e0230567.
5. Kellerborg K, Brouwer W, van Baal P. Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature. *European Journal of Health Economics* 2020; 21(9): 1329-1350.
6. Halton K, Sarna M, Barnett A, Leonardo L, Graves N. A systematic review of community-based interventions for emerging zoonotic infectious diseases in Southeast Asia. *JBI Database of Systematic Reviews and Implementation Reports* 2013; 11(2): 1-235.
7. Shi N, Huang J, Zhang X, et al. Interventions in live poultry markets for the control of avian influenza: A systematic review and meta-analysis. *The Journal of Infectious Diseases* 2020; 221(4): 553-560.
8. Prieto-Lara E, Llanos-Méndez A. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature. *Vaccine* 2010; 28(26): 4328-4334.
9. Zhang K, Wu X, Shi Y, Gou X, Huang J. Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis. *Human Vaccines & Immunotherapeutics* 2021; 17(2): 475-484.
10. Keitel WA, Voronca DC, Atmar RL, et al. Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. *Vaccine* 2019; 37(37): 5535-5543.
11. Saouaf OM, Ou BS, Song YE, et al. Sustained vaccine exposure elicits more rapid, consistent, and broad humoral immune responses to multivalent influenza vaccines. *bioRxiv* 2024: 2024.04.28.591370.
12. Zheng D, Gao F, Zhao C, et al. Comparative effectiveness of H7N9 vaccines in healthy individuals. *Human Vaccines & Immunotherapeutics* 2019; 15(1): 80-90.
13. Hsu SM, Chen TH, Wang CH. Efficacy of avian influenza vaccine in poultry: a meta-analysis. *Avian Diseases* 2010; 54(4): 1197-209.
14. Mo J, Spackman E, Swayne DE. Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review. *Vaccine* 2023; 41(38): 5507-5517.
15. Focosi D, Franchini M, Senefeld JW, et al. Passive immunotherapies for the next influenza pandemic. *Reviews in Medical Virology* 2024; 34(3): e2533.
16. Tisza MJ, Hanson BM, Clark JR, et al. Virome Sequencing Identifies H5N1 Avian Influenza in Wastewater from Nine Cities. *medRxiv* 2024: 2024.05.10.24307179.

17. Wolfe MK, Duong D, Shelden B, et al. Detection of hemagglutinin H5 influenza A virus sequence in municipal wastewater solids at wastewater treatment plants with increases in influenza A in spring, 2024. *medRxiv* 2024: 2024.04.26.24306409.
18. Morris SE, Gilmer M, Threlkel R, et al. Detection of novel influenza viruses through community and healthcare testing: Implications for surveillance efforts in the United States. *medRxiv* 2024: 2024.02.02.24302173.

Bain T, Bhuiya A, Waddell K, DeMaio, Alam S, Wang Q, Ciurea P, Wu N, Chen K, Wilson MG. Living evidence profile #8.2: Identifying features and impacts of public health strategies that can be used to prevent, reduce, and/or mitigate avian influenza spillover to humans. Hamilton: McMaster Health Forum, 17 May 2024.

This living evidence profile was funded by the Public Health Agency of Canada. The McMaster Health Forum receives both financial and in-kind support from McMaster University. The views expressed in the living evidence profile are the views of the authors and should not be taken to represent the views of the Public Health Agency of Canada or McMaster University. The authors wish to thank Angela Wang, Ariana Jaspal, Yao Maclean, and Tresha Sivanesanathan for conducting the AMSTAR appraisals.